Press releases

19 November, 2026

Notice of extraordinary general meeting in Nanexa AB (publ)

The shareholders in Nanexa AB (publ), reg.no 556833-0285 (the ”Company”) are hereby given notice that an extraordinary general meeting will be held on Monday, 14 December 2026 at 15:00 at the Company’s premises at Virdings Allé 2,

Read more

5 November, 2026

Nanexa publishes interim report for July-September 2026

A strategically important third quarter for Nanexa, marked by an agreement with Novo and scientific and operational progress

Read more

24 September, 2026

Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables

• The agreement grants Novo a global exclusive license to Nanexa’s proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity,

Read more

Latest reports

Presentations

25 September 2026

David Westberg and Göran Ando presents the Novo agreement with Q&A – Sept 25th

27 August 2026

Q2 report commentary with CEO David Westberg

18–20 May 2026

Nanexa participated in DDF Summit 2026 in Berlin, Germany on 18-20 May

Read the presentation

Meet Nanexa

Prenumerera